Rituximab as second-line therapy after new direct antiviral agents in peripheral neuropathy Hepatitis C Virus related: always correct therapeutic approach?

Acta Gastroenterol Belg. 2020 Oct-Dec;83(4):672-673.

Authors

E Mauro¹, P Passadore², L Quartuccio³, S De Vita³, A Ermacora⁴, V Gattei⁵, C Mazzaro⁵

Affiliations

¹ Department Internal Medicine, Hematology Unit, Ca'Foncello Hospital, Treviso, Italy.
² Department Neurology Unit, General Hospital Pordenone, Italy.
³ Rheumatology Clinic, University of Udine, Udine, Italy.
⁴ Department Medicine Unit, General Hospital Pordenone, Italy.
⁵ Clinical of Experimental Onco-Haematology Unit, CRO Aviano National Cancer Institute, IRCCS, Aviano (PN) Italy.

PMID: 33321031

No abstract available

Publication types

Letter

MeSH terms

Antiviral Agents / therapeutic use
Hepacivirus / genetics
Hepatitis B virus
Hepatitis C* / drug therapy
Humans
Peripheral Nervous System Diseases* / chemically induced
Peripheral Nervous System Diseases* / drug therapy
Rituximab / therapeutic use
Virus Activation

Substances

Antiviral Agents
Rituximab